Q1 2025 · 13F-HR
SR ONE CAPITAL MANAGEMENT, LPholdings as filed
Filed 2025-05-13 · accession 0000950123-25-004926
$389.3M
Reported value
12
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03940C100 | ACLXGBX | Arcellx, Inc. | $153.9M | 39.5% | 2,346,630 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals, Inc. | $50.5M | 13.0% | 4,012,903 | Common | SOLE |
| 603170101 | MLYS | Mineralys Therapeutics Inc. | $49.7M | 12.8% | 3,127,933 | Common | SOLE |
| 98937L105 | ZBIO | Zenas BioPharma, Inc | $38.8M | 9.97% | 4,911,539 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $35.7M | 9.17% | 1,048,951 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $25.2M | 6.47% | 6,526,476 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $12.0M | 3.09% | 1,959,896 | Common | SOLE |
| H5870P102 | OCS | Oculis Holding AG | $6.1M | 1.58% | 322,500 | Common | SOLE |
| 65487U108 | NKTX | Nkarta, Inc. | $6.1M | 1.58% | 3,333,333 | Common | SOLE |
| 687604108 | ORKA | Oruka Therapeutics, Inc | $4.4M | 1.13% | 430,330 | Common | SOLE |
| 483119202 | KALAEUR | KALA Bio, Inc. | $3.4M | 0.88% | 598,940 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $3.3M | 0.86% | 747,750 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.